Gilead Sciences Secures Additional Investment to Expand HIV Prevention Drug Access to 3 Million People
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy GILD?
Gilead Sciences announced that the U.S. State Department, the United States President's Emergency Plan for AIDS Relief and The Global Fund will further invest in Gilead's twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028. Bringing together the resources and expertise of both PEPFAR and The Global Fund is a key component of Gilead's larger coordinated efforts to advance access to lenacapavir for HIV PrEP. These partners are experts in country delivery and distribution, with the reach and infrastructure to ensure these supplies reach those with the greatest need as quickly as possible. Lenacapavir is the first HIV prevention therapy to reach communities in sub-Saharan Africa in the same year it was approved in the United States, with initial shipments arriving at the end of 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to fall
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 138.550
Low
105.00
Averages
137.88
High
154.00
Current: 138.550
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gilead Secures Regulatory Approval for Arcellx Acquisition
- Acquisition Approval: Gilead announced it has obtained all necessary regulatory approvals for the acquisition of Arcellx, marking a significant milestone that is expected to enhance Gilead's market position in the biopharmaceutical sector.
- Tender Offer Extension: Gilead has extended the expiration date of its tender offer for Arcellx to April 27, 2026, ensuring that the transaction can be completed smoothly upon satisfying all closing conditions, thereby strengthening its foothold in oncology.
- Shareholder Response: As of April 16, 2026, approximately 10,271,823 shares of Arcellx have been validly tendered, representing about 17.5% of the outstanding shares, indicating positive shareholder response that may support subsequent integration efforts.
- Future Outlook: Gilead aims to achieve over $6 billion in global sales of Arcellx's product by 2030, which, if realized, will trigger a $5 cash payment for holders of the contractual contingent value rights, further boosting investor confidence.
See More
Gilead Extends Tender Offer Deadline for Arcellx Acquisition
- Tender Offer Extension: Gilead has extended the deadline for its tender offer to acquire Arcellx until 5 PM ET on April 27, demonstrating the company's flexibility in response to market conditions and aiming to increase shareholder participation.
- Share Tender Status: As of April 16, nearly 18% of Arcellx's outstanding shares have been tendered, up from approximately 7.5% as of March 31, indicating growing shareholder acceptance of the acquisition proposal and enhancing the likelihood of a successful transaction.
- Regulatory Approvals Secured: Gilead has obtained all necessary regulatory approvals, including clearances from Austrian antitrust authorities, which lays a solid foundation for the smooth completion of the deal, ensuring the company can close the acquisition as planned in Q2.
- Acquisition Context: Gilead announced its intention to acquire Arcellx for $7.8 billion in February, having already owned about 12% of its outstanding shares, and the successful acquisition will further solidify its market position in the biopharmaceutical sector.
See More
Jim Cramer's Insights on Stocks
- Gilead Sciences Outlook: Cramer expresses a positive view on Gilead Sciences, praising CEO Daniel O'Day's leadership and suggesting that the company has solid business fundamentals, recommending investors hold the stock for potential gains.
- AST SpaceMobile Potential: Cramer shows optimism for AST SpaceMobile, highlighting its unique market positioning that could present investment opportunities; while he does not explicitly call for a takeover, he draws parallels to Global Star and Amazon, hinting at possible upside.
- Nokia Growth Expectations: Cramer advises investors to hold onto Nokia shares, believing the company has another 30% upside potential, reflecting confidence in its future performance.
- Investor Education Resources: Cramer encourages investors to download his investment guide and join the CNBC Investing Club to better understand market dynamics and investment strategies, aiding them in achieving long-term wealth growth.
See More
Gilead Sciences and Nokia Stock Outlook Analysis
- Gilead Sciences Outlook: Analysts express admiration for Gilead Sciences' CEO Daniel O'Day, suggesting that the company has solid business fundamentals, recommending investors to hold the stock, which reflects confidence in its future growth.
- AST SpaceMobile Potential: Analysts highly recognize AST SpaceMobile's unique assets, and while not explicitly calling for a takeover, comparisons to Global Star and Amazon imply that the company may possess attractive potential for investors.
- Nokia Growth Potential: Analysts recommend investors to hold Nokia stock, believing there is still a 30% growth potential ahead, indicating an optimistic outlook on the company's market performance.
- Market Investment Strategy: The positive comments from analysts suggest that despite market volatility, stocks like Gilead Sciences and Nokia are still viewed as attractive investment options, potentially drawing the attention of long-term investors.
See More
Gilead Expands Access to HIV Prevention Drug Lenacapavir
- Expanded Coverage: Gilead announced a partnership with the U.S. State Department, PEPFAR, and The Global Fund to increase access to lenacapavir for an additional 1 million people over the next three years, raising the total commitment to 3 million, significantly enhancing HIV prevention in high-incidence areas.
- Global Strategic Collaboration: By collaborating with PEPFAR and The Global Fund, Gilead leverages their expertise in country delivery and distribution to ensure lenacapavir reaches the communities in greatest need swiftly, thereby accelerating global access to HIV prevention medications.
- Long-Acting Drug Rollout: As the first HIV prevention therapy approved in the U.S., lenacapavir is expected to see a large-scale generic rollout starting in 2027, which will further reduce drug costs and expand market coverage, aiding the global fight against the HIV epidemic.
- Commitment to Innovation: Gilead's ongoing innovation in the HIV field has led to the development of 13 HIV medications, and plans to accelerate generic production through voluntary licensing agreements with six generic manufacturers to meet the growing global demand for HIV prevention.
See More
Morgan Stanley Raises Gilead Price Target to $175, Maintains Overweight Rating
- Price Target Increase: Morgan Stanley raised Gilead's (GILD) price target from $171 to $175, reflecting an optimistic outlook on the company's future performance, which is expected to boost investor confidence and potentially drive the stock price higher.
- Rating Maintained: The firm continues to assign an Overweight rating to Gilead, indicating analysts' recognition of its long-term growth potential, which may attract more institutional investors to the stock.
- Model Adjustments: Morgan Stanley adjusted its models across its biopharma coverage to reflect IQVIA trends and intra-quarter updates, demonstrating keen insights into industry dynamics that will aid in more accurately forecasting the company's performance.
- Market Reaction Anticipation: With the first-quarter earnings report approaching, the heightened market focus on Gilead, combined with the analysts' positive rating and price target increase, is likely to stimulate stock price appreciation ahead of the earnings release, enhancing market confidence in its future performance.
See More
Gilead Secures Regulatory Approval for Arcellx Acquisition
- Acquisition Approval: Gilead announced it has obtained all necessary regulatory approvals for the acquisition of Arcellx, marking a significant milestone that is expected to enhance Gilead's market position in the biopharmaceutical sector.
- Tender Offer Extension: Gilead has extended the expiration date of its tender offer for Arcellx to April 27, 2026, ensuring that the transaction can be completed smoothly upon satisfying all closing conditions, thereby strengthening its foothold in oncology.
- Shareholder Response: As of April 16, 2026, approximately 10,271,823 shares of Arcellx have been validly tendered, representing about 17.5% of the outstanding shares, indicating positive shareholder response that may support subsequent integration efforts.
- Future Outlook: Gilead aims to achieve over $6 billion in global sales of Arcellx's product by 2030, which, if realized, will trigger a $5 cash payment for holders of the contractual contingent value rights, further boosting investor confidence.
See More
Gilead Extends Tender Offer Deadline for Arcellx Acquisition
- Tender Offer Extension: Gilead has extended the deadline for its tender offer to acquire Arcellx until 5 PM ET on April 27, demonstrating the company's flexibility in response to market conditions and aiming to increase shareholder participation.
- Share Tender Status: As of April 16, nearly 18% of Arcellx's outstanding shares have been tendered, up from approximately 7.5% as of March 31, indicating growing shareholder acceptance of the acquisition proposal and enhancing the likelihood of a successful transaction.
- Regulatory Approvals Secured: Gilead has obtained all necessary regulatory approvals, including clearances from Austrian antitrust authorities, which lays a solid foundation for the smooth completion of the deal, ensuring the company can close the acquisition as planned in Q2.
- Acquisition Context: Gilead announced its intention to acquire Arcellx for $7.8 billion in February, having already owned about 12% of its outstanding shares, and the successful acquisition will further solidify its market position in the biopharmaceutical sector.
See More
Jim Cramer's Insights on Stocks
- Gilead Sciences Outlook: Cramer expresses a positive view on Gilead Sciences, praising CEO Daniel O'Day's leadership and suggesting that the company has solid business fundamentals, recommending investors hold the stock for potential gains.
- AST SpaceMobile Potential: Cramer shows optimism for AST SpaceMobile, highlighting its unique market positioning that could present investment opportunities; while he does not explicitly call for a takeover, he draws parallels to Global Star and Amazon, hinting at possible upside.
- Nokia Growth Expectations: Cramer advises investors to hold onto Nokia shares, believing the company has another 30% upside potential, reflecting confidence in its future performance.
- Investor Education Resources: Cramer encourages investors to download his investment guide and join the CNBC Investing Club to better understand market dynamics and investment strategies, aiding them in achieving long-term wealth growth.
See More
Gilead Sciences and Nokia Stock Outlook Analysis
- Gilead Sciences Outlook: Analysts express admiration for Gilead Sciences' CEO Daniel O'Day, suggesting that the company has solid business fundamentals, recommending investors to hold the stock, which reflects confidence in its future growth.
- AST SpaceMobile Potential: Analysts highly recognize AST SpaceMobile's unique assets, and while not explicitly calling for a takeover, comparisons to Global Star and Amazon imply that the company may possess attractive potential for investors.
- Nokia Growth Potential: Analysts recommend investors to hold Nokia stock, believing there is still a 30% growth potential ahead, indicating an optimistic outlook on the company's market performance.
- Market Investment Strategy: The positive comments from analysts suggest that despite market volatility, stocks like Gilead Sciences and Nokia are still viewed as attractive investment options, potentially drawing the attention of long-term investors.
See More
Gilead Expands Access to HIV Prevention Drug Lenacapavir
- Expanded Coverage: Gilead announced a partnership with the U.S. State Department, PEPFAR, and The Global Fund to increase access to lenacapavir for an additional 1 million people over the next three years, raising the total commitment to 3 million, significantly enhancing HIV prevention in high-incidence areas.
- Global Strategic Collaboration: By collaborating with PEPFAR and The Global Fund, Gilead leverages their expertise in country delivery and distribution to ensure lenacapavir reaches the communities in greatest need swiftly, thereby accelerating global access to HIV prevention medications.
- Long-Acting Drug Rollout: As the first HIV prevention therapy approved in the U.S., lenacapavir is expected to see a large-scale generic rollout starting in 2027, which will further reduce drug costs and expand market coverage, aiding the global fight against the HIV epidemic.
- Commitment to Innovation: Gilead's ongoing innovation in the HIV field has led to the development of 13 HIV medications, and plans to accelerate generic production through voluntary licensing agreements with six generic manufacturers to meet the growing global demand for HIV prevention.
See More
Morgan Stanley Raises Gilead Price Target to $175, Maintains Overweight Rating
- Price Target Increase: Morgan Stanley raised Gilead's (GILD) price target from $171 to $175, reflecting an optimistic outlook on the company's future performance, which is expected to boost investor confidence and potentially drive the stock price higher.
- Rating Maintained: The firm continues to assign an Overweight rating to Gilead, indicating analysts' recognition of its long-term growth potential, which may attract more institutional investors to the stock.
- Model Adjustments: Morgan Stanley adjusted its models across its biopharma coverage to reflect IQVIA trends and intra-quarter updates, demonstrating keen insights into industry dynamics that will aid in more accurately forecasting the company's performance.
- Market Reaction Anticipation: With the first-quarter earnings report approaching, the heightened market focus on Gilead, combined with the analysts' positive rating and price target increase, is likely to stimulate stock price appreciation ahead of the earnings release, enhancing market confidence in its future performance.
See More
